This is a pharmacological preclinical longitudinal study of the dose–response and efficacy of subretinal delivery of AAV5-hNR2E3 to ameliorate and attenuate retinal degeneration when administered during early (postnatal day (P) 30) or intermediate (3-months of age) disease progression in the RP mouse model rd7 1, 3, and 6 months after treatment. The gene discussed is NR2E3; the disease is retinal degeneration.